| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 03/19/2008 | CN100375635C Water soluble anti-cancer medicine slow-release fiber preparation and preparing method therefor |
| 03/19/2008 | CN100375619C Medicinal compositions improving brain function and method for improving brain function |
| 03/18/2008 | US7345154 growth hormone supergene family; prolongs circulating half-lives of protein therapeutics in the body so proteins do not have to be injected frequently; adding cysteine residues to non-essential regions using site-directed mutagenesis; covalently coupling a cysteine-reactive polymer via the added cysteine |
| 03/18/2008 | US7345151 Antagonists specific for denatured collagen and methods of using same |
| 03/18/2008 | US7345088 Synergistic mixtures |
| 03/18/2008 | US7345065 Using adrenergic receptors; side effect reduction |
| 03/18/2008 | US7345051 For controlling mucin over-production associated with diseases such as chronic obstructive pulmonary diseases including asthma and chronic bronchitis, inflammatory lung diseases, cystic fibrosis and acute or chronic respiratory infections |
| 03/18/2008 | US7345039 Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer |
| 03/18/2008 | US7345037 ipratropium/flutropium/tiotropium derivatives; anticholinergic agent; linked at NO or NO2 group, or group which stimulates endogenous production of NO; beneficial therapeutic effects; asthma, respiratory disorder, cystic fibrosis; synergistic with NO release agent or substrate for nitric oxide synthase |
| 03/18/2008 | US7345035 Downregulating mRNA encoding osteopontin by administering to a cell or mammal an effective amount of astrogorgiadiol; treatment of osteoporosis, systemic lupus erythematosis or multiple sclerosis |
| 03/18/2008 | US7345024 Pharmaceutical preparation, method for its production as well as its use |
| 03/18/2008 | US7344869 Isolated DNA comprising one or more genes specific for 5S clavam biosynthesis, vectors comprising such DNA and Streptomyces hosts capable of improved clavulanic acid production |
| 03/18/2008 | US7344829 Methods for detecting the efficacy of anticancer treatments |
| 03/18/2008 | US7344716 Transdiscal administration of specific inhibitors of pro-inflammatory cytokines |
| 03/18/2008 | US7344711 Administering an adenovirus defective in its VAI and VAII virus-associated RNAs |
| 03/18/2008 | US7344710 Aministering synergistic mixture of Clostridium spores and anticancer agents |
| 03/18/2008 | CA2345248C Use of prostanoid antagonists for the treatment of primary headache disorders |
| 03/18/2008 | CA2329128C Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces |
| 03/18/2008 | CA2328955C Fetal testing for prediction of low birth weight |
| 03/18/2008 | CA2323839C Treatment of neuropathy |
| 03/18/2008 | CA2315927C Oral pharmaceutical pulsed release dosage form |
| 03/18/2008 | CA2315395C Compositions and methods for treatment of alopecia |
| 03/18/2008 | CA2275889C Formulation and method for treating neoplasms by inhalation |
| 03/18/2008 | CA2275663C Pharmaceutical compositions comprising .alpha.-adrenergic agonists for the treatment of fecal incontinence |
| 03/18/2008 | CA2219659C Rapamycin derivatives |
| 03/18/2008 | CA2211677C Taste masking liquids |
| 03/18/2008 | CA2167980C Cgrp antagonist used in a cosmetic composition; pharmaceutical or dermatologic composition produced |
| 03/13/2008 | WO2008030651A1 Combinations containing a 4-acylaminopyridine derivative |
| 03/13/2008 | WO2008029871A1 Nerve fiber degeneration inhibitor |
| 03/13/2008 | WO2008029868A1 Ocular fibrous neovascularization inhibitor |
| 03/13/2008 | WO2008029836A1 Study, determination or evaluation method |
| 03/13/2008 | WO2008029601A1 Cancer therapeutic agent comprising ligand for neuromedin u receptor 2 (fm4) molecule as active ingredient |
| 03/13/2008 | WO2008029493A1 Nerve fiber degeneration inhibitor |
| 03/13/2008 | WO2008029237A2 Combination therapies for rheumatoid arthritis |
| 03/13/2008 | WO2008028903A2 Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer |
| 03/13/2008 | WO2008012290A3 Quinuclidine derivatives as m3 antagonists |
| 03/13/2008 | WO2007144422A3 Combination preparations comprising bifeprunox and l-dopa |
| 03/13/2008 | WO2007125310A3 Pharmaceutical combinations of pk inhibitors and other active agents |
| 03/13/2008 | WO2007095583A3 Methods for treating cancer and sensitizing cancer cells using the serine protease inhibitor, maspin |
| 03/13/2008 | WO2007092270A3 Combination therapy for coronary artery disease |
| 03/13/2008 | WO2007079391A3 Drug delivery system for bioadhesion to a vulvovaginal surface |
| 03/13/2008 | US20080064854 Composition of a polypeptide and an amphiphilic compound in an ionic complex and the use thereof |
| 03/13/2008 | US20080064764 Isolated nucleic acids; antibody for selective binding; biodrug treating osteoporosis, osteoblast, bone disorders, osteocalcin mediated disorder |
| 03/13/2008 | US20080064724 Composition Comprising Methylphenidate and Another Drug |
| 03/13/2008 | US20080064670 Including Premenstrual Dysphoric Disorder; administering ethinyl estradiol and levonorgestrel in combination for 81 to 89 consecutive days followed by only ethinyl estradiol for 7 consecutive days and an antidepressant intermittantly administered |
| 03/13/2008 | US20080064651 A 21-base antisense oligonucleotide which inhibits gene expression of testosterone-repressed prostate message-2 by tumor cells; prostate and renal cell cancer; enhanced chemosensitivity, hormone and radiation sensitivities |
| 03/13/2008 | US20080064633 Preventing fibronectin deposition and fibrosis; phospholipase A2 inhibition; cystic fibrosis |
| 03/13/2008 | US20080064096 Isolated nucleic acid molecules which encode a soluble IL-TIF receptor or binding protein which binds to IL-TIF/IL-22, and uses thereof |
| 03/13/2008 | US20080063687 Injectable sustained release delivery devices |
| 03/13/2008 | US20080063626 Minimization of drug oxidation in drug irradiated excipients formulations |
| 03/13/2008 | US20080063624 administering compounds which bind to the chemokine receptors, such as 1,1'-[1,4-phenylene-bis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane, optionally with colony stimulating factors, to effect regeneration of dead myocardium |
| 03/13/2008 | US20080063608 Pharmaceutical Compositions for Inhalation Containing an Anticholinergic, Corticosteroid, and Betamimetic |
| 03/13/2008 | US20080063600 use of deactivated lymphocytes, antibodies, drug mixtures and adjuvants, for the treatment or prevention of Cruetzfield-Jacobs disease in humans or animals; immunology; bioassays |
| 03/13/2008 | DE10107659B4 Mucoadhäsive zerfallsfähige Arzneizubereitung zur Wirkstoffverabreichung in der Veterinär- und Humanmedizin Mucoadhesive disintegratable pharmaceutical preparation for drug delivery in veterinary and human medicine |
| 03/13/2008 | CA2662491A1 Combinations containing a 4-acylaminopyridine derivative |
| 03/13/2008 | CA2656227A1 Cancer therapeutic agents comprising a ligand for the neuromedin u receptor 2 (fm4) molecule as an active ingredient |
| 03/12/2008 | EP1897949A2 Human interleukin-B50. Therapeutic uses |
| 03/12/2008 | EP1897889A2 Method of modulating the profileration of medullary thyroid carcinoma cells |
| 03/12/2008 | EP1897561A1 Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents |
| 03/12/2008 | EP1897558A1 Solid preparation |
| 03/12/2008 | EP1897553A1 Inhibitor of stem cell proliferation and uses thereof |
| 03/12/2008 | EP1897547A1 Use of pyridoxal phosphate derivatives for the treatment of diabetes and related complications |
| 03/12/2008 | EP1897546A1 Combined compositions comprising (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid |
| 03/12/2008 | EP1897540A2 Inhibition of STAT3 signal transduction for human cancer therapy |
| 03/12/2008 | EP1897539A1 Anti-fatigue composition |
| 03/12/2008 | EP1897450A1 Compound containing alpha lipoic acid |
| 03/12/2008 | EP1896489A1 Salts or complexes of methyl donors with phytic acid or its derivatives and method for the synthesis thereof |
| 03/12/2008 | EP1896136A2 Compositions having an activity of ameliorating a reduced higher brain function resulting from organic brain lesions |
| 03/12/2008 | EP1896134A2 Methods and compositions for treating degenerative bone disorders |
| 03/12/2008 | EP1896077A2 Methods and compositions for the prevention and treatement of inflammatory disease |
| 03/12/2008 | EP1896076A2 Compositions and methods for enhancement of sexual function |
| 03/12/2008 | EP1896075A2 Pharmaceutical compositions comprising tacrolimus and a cyp3a4 inhibitor |
| 03/12/2008 | EP1896074A1 Pharmaceutical compositions for treating or preventing coronary artery disease |
| 03/12/2008 | EP1896042A2 Methods and reagents for the treatment of inflammatory disorders |
| 03/12/2008 | EP1896007A2 Method of administering a cationic liposomal preparation comprising paclitexel |
| 03/12/2008 | EP1895987A2 Composition and method for inhibiting, preventing, or ameliorating complications associated with ingestion of a medicinal, chemical, or biological substance or agent |
| 03/12/2008 | EP1768602A4 Combination drug therapy for reducing scar tissue formation |
| 03/12/2008 | EP1539693B1 Cannabinoid receptor agonists |
| 03/12/2008 | EP1506317B1 Marker molecules associated with lung tumors |
| 03/12/2008 | EP1450775B1 C-kit inhibitors for treating bacterial infections |
| 03/12/2008 | EP1450751B1 Nanoparticle delivery vehicle |
| 03/12/2008 | EP1414809B1 Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation |
| 03/12/2008 | EP1408999B1 Compositions addressing inflammation and/or degenerative disorders |
| 03/12/2008 | EP1210434B1 Mammalian interleukin-12 p40 and interleukin b30. combinations thereof. antibodies. uses in pharmaceutical compositions |
| 03/12/2008 | EP1178803B1 Opioid antagonists containing compositions for enhancing analgesic potency of tramadol and attenuating its adverse side effects |
| 03/12/2008 | CN101141982A Method and pharmaceutical composition for treating psoriasis, squamous cell carcinoma and/or parakeratosis by inhibiting expression of squamous cell carcinoma-related antigen |
| 03/12/2008 | CN101138637A Antineoplastic medicament and adenovirus composite preparations and uses thereof |
| 03/12/2008 | CN101138635A Fibrin glue vasodilation agent sustained-release long-acting composition |
| 03/12/2008 | CN101138634A Composition for treating tumour |
| 03/12/2008 | CN101138563A Pharmaceutical composition for treating peptic ulcer |
| 03/12/2008 | CN101138558A Pentamidine and death domain receptor ligand united application |
| 03/12/2008 | CN101138550A Mixed glue bundle pharmaceutical preparations produced in combination use of multiple surfactant and processes for their preparation |
| 03/12/2008 | CN101138546A Restrainer containing tyrosine kinase and anticancer hormone medicines composition |
| 03/12/2008 | CN100374440C Spirosubstituted piperidines as selective melanin concentrating hormone receptor antagonists for the treatment of obesity |
| 03/12/2008 | CN100374425C Aryl and heteroaryl urea CHK1 inhibitors for use as radiosensitizers and chamosensitizers |
| 03/12/2008 | CN100374163C Composition for the enhancement of the efficacy of drugs |
| 03/12/2008 | CN100374162C application of seasquirts-743 on preparing agent for the treatment of tumor |
| 03/12/2008 | CN100374161C Triacetin as a transdermal penetration enhancer |
| 03/12/2008 | CN100374160C Anti-cancer medicine composition containing antimetabolite |
| 03/12/2008 | CN100374159C Preventives or remedies for inflammatory intestinal diseases contg. as active ingredient IL-6 antagonists |